1400688-75-6Relevant academic research and scientific papers
Discovery of pyrrolo[1,2-b]pyridazine-3-carboxamides as Janus kinase (JAK) inhibitors
Duan, James J.-W.,Lu, Zhonghui,Jiang, Bin,Yang, Bingwei V.,Doweyko, Lidia M.,Nirschl, David S.,Haque, Lauren E.,Lin, Shuqun,Brown, Gregory,Hynes, John,Tokarski, John S.,Sack, John S.,Khan, Javed,Lippy, Jonathan S.,Zhang, Rosemary F.,Pitt, Sidney,Shen, Guoxiang,Pitts, William J.,Carter, Percy H.,Barrish, Joel C.,Nadler, Steven G.,Salter-Cid, Luisa M.,McKinnon, Murray,Fura, Aberra,Schieven, Gary L.,Wrobleski, Stephen T.
, p. 5721 - 5726 (2014)
A new class of Janus kinase (JAK) inhibitors was discovered using a rationally designed pyrrolo[1,2-b]pyridazine-3-carboxamide scaffold. Preliminary studies identified (R)-(2,2-dimethylcyclopentyl)amine as a preferred C4 substituent on the pyrrolopyridazi
PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES
-
, (2012/10/07)
Disclosed are compounds of Formula (I), and pharmaceutically acceptable salts thereof. The compounds of formula (I) inhibit tyrosine kinase activity of JAK3, thereby making them useful for the treatment of inflammatory and autoimmune diseases.
PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES
-
Page/Page column 67, (2012/10/07)
Disclosed are compounds of formula (I) and pharmaceutically acceptable salts thereof. The compounds of formula (I) inhibit tyrosine kinase activity of JAK3, thereby making them useful for the treatment of inflammatory and autoimmune diseases.
